Evidence map›Paper›PMID 27354268›Full record

ArticleCancer discovery2016

Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia.

Sophia E Maharry, Christopher J Walker, Sandya Liyanarachchi, Sujay Mehta, Mitra Patel, Maryam A Bainazar, Xiaomeng Huang, Malori A Lankenau, Kevin W Hoag, Parvathi Ranganathan and 6 more

Open access · greenAbstract read
In one paragraph

Article in Cancer discovery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Circ_03955 promotes pancreatic cancer tumorigenesis and Warburg effect by targeting the miR-3662/HIF-1α axis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Sophia E MaharryThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Christopher J WalkerThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Sandya LiyanarachchiThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Sujay MehtaThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Mitra PatelThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Maryam A BainazarThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Xiaomeng HuangThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Malori A LankenauThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Kevin W HoagThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Parvathi RanganathanThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ramiro GarzonThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
James S BlachlyThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Denis C GuttridgeThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Clara D BloomfieldThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Albert de la ChapelleThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Ann-Kathrin EisfeldThe Ohio State University Comprehensive Cancer Center, Columbus, Ohio. ann-kathrin.eisfeld@osumc.edu.
The Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
SPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2M
Cancer and Leukemia Group B Human Specimen RepositoriesU24CA114725 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 2005 to 2014
$11.1M
ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" TherapieU10CA180861 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D, MARCUCCI, GUIDO · 2014 to 2018
$3.4M
Role of RNA-Binding Proteins in BCR/ABL LeukemogenesisR01CA095512 · NCI · OHIO STATE UNIVERSITY · PI PERROTTI, DANILO · 2003 to 2012
$2.2M
NCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS R01 CA095512NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA180861NCI NIH HHS U24 CA114725
6 · The paper itself

Abstract

unlabelledChromosomal aberrations and multiple genome-wide association studies (GWAS) have established a major hematopoietic quantitative trait locus in chromosome 6q23.3. The locus comprises an active enhancer region, in which some of the associated SNPs alter transcription factor binding. We now identify miR-3662 as a new functional driver contributing to the associated phenotypes. The GWAS SNPs are strongly associated with higher miR-3662 expression. Genome editing of rs66650371, a three-base-pair deletion, suggests a functional link between the SNP genotype and the abundance of miR-3662. Increasing miR-3662's abundance increases colony formation in hematopoietic progenitor cells, particularly the erythroid lineage. In contrast, miR-3662 is not expressed in acute myeloid leukemia cells, and its overexpression has potent antileukemic effects in vitro and in vivo Mechanistically, miR-3662 directly targets NF-κB-mediated transcription. Thus, miR-3662 is a new player of the hematopoietic 6q23.3 locus. SIGNIFICANCE: The characterization of miR-3662 has identified a new actor in the prominent hematopoietic quantitative trait locus in chromosome 6q23.3. The mechanistic insights into miR-3662's function may reveal novel or only partially known pathways for normal and malignant hematopoietic cell proliferation. Cancer Discov; 6(9); 1036-51. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 932.

Indexed as

Chromosomes, Human, Pair 6Gene Expression Regulation, LeukemicQuantitative Trait LociAllelesAnimalsBinding SitesCCAAT-Enhancer-Binding ProteinsCell ProliferationCell SurvivalCell Transformation, NeoplasticColony-Forming Units AssayDisease Models, AnimalFemaleGATA1 Transcription FactorGene DosageGenetic Association StudiesCCAAT-Enhancer-Binding ProteinsGATA1 Transcription FactorI-kappa B KinaseMicroRNAsMIRN-3662 microRNA, humanNF-kappa B

Identifiers

PMID27354268
PMCPMC5168803
OpenAlexW2464518668

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.